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Evelyn Regar, MD, PhD, FESC, a Eveline Nüesch, PhD, b Francesco Borgia, MD, d
Willem J. van der Giessen, MD, PhD, FESC, a Simon Davies, MD, d Robert Jan van Geuns, MD, PhD, FESC, a
Gioel Gabrio Secco, MD, d Susanne Meis, MD, e Stephan Windecker, MD, FESC, f
Patrick W. Serruys, MD, PhD, FESC, FACC, a and Carlo di Mario, MD, PhD, FESC, FACC d Rotterdam, The
Netherlands; Bern, and Morges, Switzerland; and London, United KingdomBackground Biolimus-eluting stents (BESs) with a biodegradable polymer in abluminal coating achieve more complete
coverage at 9 months compared with sirolimus-eluting stents (SESs) with a durable polymer, as assessed by optical coherence
tomography (OCT). Whether this advantage persists or augments after complete resorption of the polymer (N12 months)
is unknown.
Methods The LEADERS trial compared the performance of BES with that of SES. Patients were randomly allocated to a
sequential angiographic follow-up, including OCT in selected sites, at 9 and 24 months. Struts coverage was compared using
Bayesian hierarchical models as the primary outcome for the OCT substudy.
Results Fifty-six patients (26 BES, 30 SES) were enrolled in the OCT substudy. Twenty-one patients (10 BES, 11 SES)
agreed to perform a second OCT follow-up at 24 months. Eleven lesions and 12 stents were analyzed sequentially in the
BES group (2,455 struts at 9 months, 2,131 struts at 24 months) and 11 lesions and 18 stents in the SES group (3,421 struts at
9 months, 4,170 struts at 24 months). The previously reported advantage of BES over SES in terms of better strut coverage
at 9 months was followed by improvement in coverage of the SES, resulting in identical coverage in both BES and SES at
24 months: 1.5% versus 1.8% uncovered struts, difference −0.2%, 95% credibility interval, −3.2% to 2.6%, P = .84.
Conclusions More complete strut coverage of BES as compared with SES at 9 months was followed by improvement of
coverage in SES between 9 and 24 months and a similar long-term coverage in both stent types at 24 months. (Am Heart J
2011;162:922-31.)Drug-eluting stents (DESs) have reduced restenosis
rates to approximately 9%,1 but they might pose a higher
risk of late and very late stent thrombosis,1 with the
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Open access under the Elsevier OA license.healing and incomplete endothelialization.2,3 In first-
generation DES, the mechanism for incomplete neointi-
mal coverage seems to go beyond the antiproliferative
potency of the drug and also involve an inflammatory
reaction.3-6 The presence of intense eosinophilic in-
filtrates in the vessel wall3 and in the thrombus harvested
from patients with very late stent thrombosis4 suggests
that inflammation might be mediated by delayed type IVb
hypersensitivity. Hypersensitivity is likely triggered by the
polymer rather than by other components of the device,6
given the timing of onset (later than 90 days, when the
drug is no longer detectable in the vessel wall) and the
presence of polymer fragments surrounded by giant
cells.3,5 An interesting approach to minimize polymer-
induced inflammation consists of coating the metallic
backbone of the stent with a biodegradable polymer




Rotation speed (Hz) 20 100
Pullback speed (mm/s) 3 20
Patients with SES 9 mo 11 0
24 mo 3 8
Patients with BES 9 mo 10 0
24 mo 3 7
⁎All systems and catheters were obtained from Lightlab Imaging.
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Volume 162, Number 5that is fully resorbed after elution of the drug.7 The risk of
delayed hypersensitivity disappears together with the
potential allergens, and complete neointimal healing is
no longer in jeopardy.
The LEADERS trial was the first published randomized
study to use optical coherence tomography (OCT) for
the evaluation of tissue coverage in 2 different types of
DES.8,9 It compared a new-generation biolimus-eluting
stent (BES) with a biodegradable polymer in abluminal
coating versus a first-generation sirolimus-eluting stent
(SES) with a durable polymer in conformal coating. At
9 months, BES showed a lower proportion of uncovered
struts compared with SES (weighted estimate 0.6% vs
2.1%, P = .04).9 The aim of this study was to assess
whether this difference persists after complete resorp-
tion of the BES polymer.
Methods
Study population and design
The design and main results from the LEADERS trial have been
published elsewhere.8 It was an international randomized
multicenter noninferiority trial comparing the BES BioMatrix
Flex stent (Biosensors International, Morges, Switzerland) with
the SES Cypher SELECT stent (Cordis, Miami Lakes, FL),
following an all-comers approach with minimal exclusion
criteria: patients with symptomatic coronary heart disease or
silent ischemia were eligible if they had at least one coronary
lesion of ≥50% diameter stenosis in vessels with 2.25- to 3.50-
mm reference diameters, amenable for percutaneous treatment.
The primary end point was a composite of cardiac death,
myocardial infarction, and clinically indicated target vessel
revascularization at 9 months of follow-up.
Patients were randomly allocated on a 1:1 basis to receive
either BES or SES using random computer-generated sequences,
stratified according to center. In a factorial design, they were
additionally randomized on a 1:3 basis to angiographic and
clinical follow-up at 9 months or clinical follow-up alone.
Patients allocated to angiographic follow-up in 2 of the study
sites (Royal Brompton Hospital [London, UK], and Erasmus MC
[Rotterdam, the Netherlands]) were also included in the OCT
substudy. Serum creatinine ≥200 mol/L and left ventricular
ejection fraction b30% were the exclusion criteria for the OCT
substudy. The primary end point for the OCT substudy was the
proportion of uncovered struts at 9 and 24 months. The study
complied with the Declaration of Helsinki, was approved by all
institutional ethics committees, and was registered at clinical-
trials.gov (NCT00389220). All patients provided written in-
formed consent for participation.
Intervention and study stents
Direct stenting was allowed, and full lesion coverage was
pursued by implanting one or several stents, as required. Only 1
type of DES was used per patient.
The BioMatrix Flex stent (Biosensors International) consists of
a stainless-steel platform (Juno; Biosensors International) coated
by an abluminal 11-μm layer of polylactide polymer. The
polymer contains Biolimus-A9 (Biosensors International,
Morges, Switzerland) at a concentration of 15.6 μg/mm ofstent length. Polylactide is linearly degraded by surface
hydrolysis to lactide during a period of 6 to 12 months, resulting
in simultaneous release of the drug.7 The Cypher SELECT stent
(Cordis) consists of a stainless-steel platform coated by a durable
blend ofpoly(ethylene-vinyl-acetate) andpoly(butyl-methacrylate)
containing sirolimus at a concentration of 8.3 to 10.4 μg/mm,
depending on the stent nominal diameter. The drug elution
period is estimated to be 90 days. After the intervention, the
patients received at least 75 mg of acetylsalicylic acid
indefinitely and dual-antiplatelet therapy with 75 mg of
clopidogrel for 12 months.OCT study and analysis
Optical coherence tomography pullbacks were obtained at 9
and 24 months of follow-up with M3 or C7 systems (Lightlab
Imaging, Westford, MA), depending on availability, using a
nonocclusive technique10 (Table I). Optical coherence tomog-
raphy pullbacks were analyzed offline in a core laboratory
(Cardialysis BV, Rotterdam, the Netherlands) by independent
staff blinded to allocation and to clinical or procedural
characteristics of the patients using proprietary software
(Lightlab Imaging). Cross sections at 1-mm intervals within the
stented segment were analyzed. Lumen and stent areas were
drawn in each cross section, and incomplete stent apposition
(ISA) or neointimal hyperplasia (NIH) areas were calculated, as
appropriate.11 Apposition was assessed per strut by placing a
marker at the adluminal leading edge, in the midpoint of the
strut's long axis, and by measuring the distance between this
marker and the lumen contour, following a straight line directed
to the center of gravity of the vessel.12 Struts were considered
malapposed if the distance was ≥170 μm (for SES) or ≥140 μm
(for BES), the thresholds resulting from rounding up the sum
of the strut-polymer thickness of each stent (SES 153 μm, BES
120 μm) plus the axial resolution of OCT (14 μm). Struts located
at the ostium of side branches, with no vessel wall behind, were
labeled as nonapposed side-branch struts and excluded from
the analysis of apposition.13,14
Struts were classified as uncovered if any part of the strut
was visibly exposed to the lumen, or as covered if a layer of
tissue was visible over all the reflecting surfaces. In covered
struts, thickness of coverage was measured from the strut
marker to the adluminal edge of the tissue, following a straight
line connecting the strut marker with the center of gravity of
the vessel.11,13–15
The clustering and spatial distribution of uncovered struts
were summarized in “spread-out vessel graphics”13 (Figure 1).
Figure 1
Examples of spatial distributions of uncovered struts in spread-out-vessel graphs. Examples of 1 BES (upper panel) and 1 SES (lower panel)
studied with OCT at 9 and 24 months. The x-axis represents the distance from the distal edge of the stent to the strut; the y-axis represents the
angle where the strut is located in the circular cross section with respect to the center of gravity of the vessel. The result is a graph representing
the spatial distribution of the noncovered struts (red spots) along the stent, as if it had been cut along the reference angle (0°) and spread out on
a flat surface.
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Prespecified primary outcome was the difference in
percentage of uncovered struts at 24 months. Assuming an
average number of 1.5 lesions per patient and 180 struts per
lesion, an intracluster correlation coefficient of 0.04 for binary
coverage of struts within lesions, and a design factor of 1.3,
we estimated that the inclusion of 22 patients (with 33 lesions
and 5,940 struts) per group would yield a greater than 90%
power to detect a difference in uncovered struts of 4% at
9 months between BESs and SESs at a 2-sided type I error of
0.05. Secondary outcomes comprised other variables assessing
coverage, ISA, and the geometric mean thickness of coverage.
To estimate the differences between BES and SES, we used a
Bayesian hierarchical random-effects model based on Markov
chain Monte Carlo simulations with minimally informative
priors.9 The model included random effects at the level of
lesions and patients, fully accounting for the correlation of
lesion characteristics within patients and their variation
between patients. We used the Wilcoxon test for continuous
variables and the Pearson χ2 or Fisher exact test as
appropriate for dichotomous variables to compare baseline
characteristics as well as areas and volumetric parameters
per stent. Statistical analyses were performed using WinBUGS
version 1.4.3 (Imperial College and Medical Research
Council, London, UK) and Stata release 11 (StataCorp, College
Station, TX).The LEADERS trial (NCT00389220) and this OCT substudy
have been sponsored by Biosensors International. The authors
are solely responsible for the design and conduct of this study,
all study analyses, the drafting and editing of the paper, and its
final contents.Results
Eighty-eight patients (43 BES, 45 SES) were allocated
to angiographic follow-up in the OCT study centers.
Optical coherence tomography studies from 46 patients
were finally analyzed at 9 months (Figure 2). All 46
patients were contacted at 24 months, but 25 refused
to participate in a second invasive follow-up (20 BES, 26
SES). Sequential OCT follow-up was analyzed in 10
patients, 11 lesions, and 12 stents in the BES group
(2,455 struts at 9 months, 2,131 struts at 24 months)
and in 10 patients, 11 lesions, and 18 stents in the SES
group (3,421 struts at 9 months, 4,170 struts at 24
months). All 9-month studies were performed with a
time-domain M3 system, whereas 15 studies at 24
months (71%) were performed with a Fourier-domain
C7 system (Table I).
Figure 2
Flowchart of the OCT study and sequential follow-up.




(n = 11) P
Age (y), mean (SD) 61.3 (6.6) 60.3 (10.8) .78
Male 7 (70) 7 (64) 1.00
Diabetes mellitus 2 (20) 2 (18) 1.00
Hypertension 3 (30) 6 (55) .39
Hypercholesterolemia 5 (50) 9 (82) .18
Smoking 3 (30) 7 (64) .20
Previous MI 4 (40) 5 (45) 1.00
Previous PCI 2 (20) 3 (27) 1.00
Previous CABG 1 (10) 1 (9) 1.00
Clinical presentation
Stable angina 6 (60) 6 (55) 1.00
Acute coronary syndrome 4 (40) 5 (45) 1.00
Unstable angina 0 (0) 2 (18)
NSTEMI 1 (10) 2 (18)
STEMI 3 (30) 1 (9)
Angiographic characteristics
No. of lesions per patient, mean (SD) 1.8 (0.9) 1.2 (0.4) .09
Multivessel disease 4 (40) 0 (0) .035
Long lesions (N20 mm) 3 (30) 6 (55) .39
Small-vessel disease (RVD b 2.75mm) 6 (60) 8 (73) .66
Results are expressed as n (%) unless otherwise indicated. MI indicates myocardial
infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass
graft; NSTEMI, non–ST elevation myocardial infarction; STEMI, ST elevation
myocardial infarction; RVD, reference vessel diameter.





(n = 11) P
Coronary artery of the target lesion .51
LAD 6 (55) 3 (27)
LCX 1 (9) 1 (9)
RCA 4 (36) 7 (64)
De novo lesions 10 (91) 11 (100)
Bifurcation 2 (18) 2 (18) 1.00
Total occlusion 5 (45) 4 (36) 1.00
Severe calcification 1 (9) 2 (18) 1.00
QCA (in-stent)
Lesion length (mm), mean (SD) 18.4 (14.6) 30.0 (29.0) .53
RVD (mm), mean (SD)
Pre-stenting 2.8 (0.5) 2.7 (0.6) .81
Post-stenting 2.5 (0.5) 2.7 (0.6) .45
9 mo 2.5 (0.4) 2.8 (0.6) .19
MLD (mm), mean (SD)
Pre-stenting 0.7 (0.8) 0.7 (0.6) .94
Post-stenting 2.3 (0.4) 2.3 (0.5) .87
9 mo 2.1 (0.8) 2.1 (0.6) .68
Late lumen loss (mm) 1.4 (0.8) 1.3 (0.4) .65
Procedural characteristics, mean (SD)
No. of study stents per lesion 1.5 (0.7) 2.0 (1.2) .33
Maximal stent diameter per lesion 3.1 (0.3) 3.1 (0.5) .87
Total stent length per lesion 28.6 (21.2) 45.5 (34.7) .18
Direct stenting 5 (45) 4 (36) 1.00
Results are expressed as n (%) unless otherwise indicated. LAD indicates left
anterior descending; LCX, left circumflex; RCA, right coronary artery; QCA,
quantitative coronary angiography; RVD, reference vessel diameter; MLD, minimal
lumen diameter.
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were comparable between both groups (Tables II and
III). Table IV shows the mean areas and volumes per
stent. At 9 months, corrected ISA volume was higher in

















Stented length (mm) 23.43 (13.87) 35.84 (24.78) .193 23.05 (13.13) 35.82 (26.20) .401
MLA (mm2) 4.86 (2.40) 4.58 (2.46) .748 4.89 (1.73) 4.96 (2.30) .898
Lumen volume (mm3) 144.69 (69.37) 252.92 (189.96) .438 145.91 (77.34) 260.44 (176.21) .300
Minimum stent area (mm2) 5.38 (2.11) 5.03 (2.18) .606 5.87 (1.52) 5.68 (2.42) .949
Stent volume (mm3) 158.79 (73.43) 263.02 (197.75) .562 170.13 (87.40) 287.54 (196.02) .365
ISA volume (mm3) 0.24 (0.45) 4.28 (10.09) .040 0.13 (0.44) 1.48 (2.11) .151
Corrected by stent volume (%) 0.15 (0.24) 1.76 (3.52) .047 0.11 (0.35) 0.78 (1.34) .171
NIH volume (mm3) 14.33 (18.57) 14.50 (18.17) 1.000 24.35 (18.86) 28.58 (29.12) .949
Percent NIH volume obstruction (%) 9.02 (10.02) 5.76 (5.03) .606 14.53 (9.57) 9.43 (5.37) .171
MLA, Minimal lumen area.
P-values ≤ 0.05 in bold.
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24 months and making the difference no longer
significant (P ≤ .171).
Figure 3 shows the evolution of coverage between 9
and 24 months in representative cross sections, matched
using fiduciary landmarks. A total of 121 of 2,455 and
69 of 2,131 struts were uncovered in the BES group at
9 and 24 months, respectively; 286 of 3,421 and 109
of 4,170 struts were uncovered in the SES group at 9 and
24 months, respectively. At 9 months, the overall
proportion of uncovered struts tended to be higher in
SES than in BES, although it did not reach conventional
levels of statistical significance (Table V). At 24 months,
the proportion of uncovered struts decreased to similar
levels in both groups (weighted percentage 2%) (Table V,
Figure 4). The spread-out-vessel charts present the
results for individual patients, showing the spatial
distribution and temporal evolution of uncovered struts
in 30 stents (Figure 5). There was little evidence for the
differences in thickness of coverage or in the variables
estimating apposition between the treatment groups at
9 or 24 months (Table V, Figure 6).Discussion
In this sequential OCT study nested in a randomized
comparison of 2 different DESs, we found that the
advantage of a BES with a biodegradable polymer in
abluminal coating over an SES with a durable polymer
in terms of strut coverage at 9 months9 was followed
by improvement of the SES coverage between 9 and
24 months, resulting in similar coverage in BES and SES at
24 months. Both types of stent converged at a maximum
plateau around 98% strut coverage. Taken together, our
results suggest that BES, indeed, is associated with faster
healing compared with SES, achieving a percentage
of coverage close to the maximum plateau (97%) at
9 months, whereas SES is catching up subsequently.To our knowledge, this is the first clinical in vivo study
using sequential OCT to compare the coverage of 2
different types of DES. Previous sequential studies had
reported SES coverage at 6 to 12 months16 and at 24 to
48 months17 using OCT, or at 4-11-21 months using
angioscopy18; the latter was compared with a control
bare metal stent.
“Very late healing” phenomenon
The improvement in coverage observed in SES
between 9 and 24 months challenges the currently
accepted evidence about the healing process after
stenting and compels us to reconsider the initial
interpretation of the 9-month results.9 Experimental
studies suggested that the reendothelialization process
ensuing a vessel injury, for example, stenting, was limited
in time.19-21 Endothelial denudation of carotid arteries is
followed by reendothelialization that stops after 2 weeks
(in the rabbit) or after 6 weeks (in the rat), although
endothelial continuity has not been restored.22,23 This
experimental evidence seemed consistent with the
results of sequential angioscopic studies in SES, showing
no improvement in the minimum coverage between 6
and 24 months, with an increase in the maximum24 and
only slight improvement in the predominant score at
4-11-21 months,18 eventually suggesting an arrested
healing process undergoing phenomena of intima matu-
ration or plaque progression. Our results question this
static time-limited model of neointimal healing, suggest-
ing a more dynamic process, still evolving between 9
and 24 months. Previous noncomparative studies using
OCT suggested also this possibility: improvement of
SES coverage has been reported at 3-24-48 months17,25,26
or between 6 and 12 months.16 Because of its high
resolution (10-20 μm) and ability for detailed analysis,
OCT could detect subtle changes in neointimal coverage,
which are unnoticed for angioscopy or other imaging
techniques. The evolution of neointimal volumes,
Figure 3
A, Representative examples of matched cross sections at 9 and 24
months in BESs showing the pattern of coverage. B, Representative
examples of matched cross sections at 9 and 24 months in SESs
showing the pattern of coverage.
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Volume 162, Number 5increasing similarly in both stent groups between 9 and
24 months (Table IV), might indicate an actively repairing
neointima but can also be the consequence of intimamaturation or plaque progression. The ISA reduction
between 9 and 24 months is more specific as an indicator
of very late healing. Higher incidence of ISA in the SES
group had been reported at 9 months9 and interpreted in
terms of late-acquired ISA. This interpretation now
becomes unlikely because the most pronounced reduc-
tion in ISA between 9 and 24 months is observed in SES.
This is in disagreement with previous sequential studies
reporting an increase in ISA areas and ISA struts between
24 and 48 months in SES.17 This discrepancy deserves
further clarification in the future.Different healing rates in different types of stent
The design of our study does not permit to elucidate the
mechanism for the different healing rates observed
between the devices. Although inflammation was the
driving hypothesis for this study and was advocated to
explain the differences reported at 9 months,9 it cannot
satisfactorily explain the very late healing. Why does the
initial advantage in coverage not persist after the
proinflammatory polymer has completely disappeared
in one of the devices? The role played by polymer-
induced inflammation6 in the neointimal healing after
stenting should be revisited: its deleterious effect might
be not as sustained in time as currently assumed, with the
exception of infrequent delayed hypersensitivity reac-
tions.3,4 The kinetics of release differ from the coverage
rates observed: the elution periods for SES and BES are
90 days and 6 to 9 months, respectively. The different
inhibitory potency, lipophilicity, concentration, or pleio-
tropic effects of biolimus and sirolimus have played a
role: the effective neointimal inhibition could be more
intense in SES than in BES. Likewise, the design and
geometry of the stent platforms could have promoted
faster healing in the BES, especially the strut thickness.
Both platforms are made of stainless steel, hence
requiring thick struts (N100 μm) to provide enough radial
strength for vessel scaffolding; but BES struts are slightly
thinner (120 μm) than SES struts (140 and 154 μm if we
add the polymer thickness), which is associated with
faster healing.27 The selective abluminal coating of BES
appears to be a more plausible explanation: the abluminal
release of the drug might modulate the proliferation of
smooth muscle cells in the media that minimally in-
terferes with the reendothelialization of the adluminal
side, thus promoting a faster reendothelialization.Clinical implications
Very late healing could be key to understanding why
clinical studies have failed to demonstrate higher rates
of stent thrombosis in SES,28 although angioscopy18,24
or OCT16,17,25,26 have reported suboptimal coverage
between 3 and 48 months. As suggested by our results
and also by other studies,18,26 longer follow-up intervals















Difference (95% CrI) P
9 mo Struts 6226 2640 3586
Coverage Uncovered struts⁎ 2.8 (0.9-7.3) 5.7 (2.0-14.3) −2.9 (−11.6 to 2.9) .31
Lesions with
≥10% uncovered struts 18.6 (2.2-60.3) 29.8 (5.2-71.7) −9.6 (−57.2 to 37.8) .66
≥5% uncovered struts 42.9 (9.8-82.9) 58.0 (17.7-90.6) −14.0 (−65.3 to 43.2) .63
Any uncovered struts 91.6 (59.5-99.4) 100.0 (92.6-100.0) −7.9 (−40.0 to 0.2) .054
Thickness of coverage (μm)† 56.7 (32.5-101.9) 41.6 (23.4-70.2) 14 (−21 to 64) .41
Apposition ISA struts 0.5 (0.2-1.5) 1.4 (0.5-3.5) −0.8 (−3.0 to 0.4) .18
Lesions with
≥10% ISA struts 0.0 (0.0-1.3) 3.2 (0.1-27.2) −3.1 (−27.2 to −0.0) .035
≥5% ISA struts 0.0 (0.0-1.3) 3.2 (0.1-27.2) −3.1 (−27.2 to −0.0) .035
Any ISA struts 73.2 (29.9-96.1) 91.6 (56.2-99.3) −16.2 (−61.8 to 22.5) .34
24 mo Struts 6490 2337 4153
Coverage Uncovered struts⁎ 1.5 (0.5-4.2) 1.8 (0.6-4.5) −0.2 (−3.2 to 2.6) .84
Lesions with
≥10% uncovered struts 2.9 (0.1-25.4) 0.0 (0.0 to −)‡ 2.9 (0.0-25.4) .012
≥5% uncovered struts 31.2 (5.5-74.3) 8.2 (0.6-41.4) 20.2 (−18.1 to 66.7) .27
Any uncovered struts 73.1 (30.1-96.0) 97.2 (74.7-100.0) −21.9 (−65.7 to 6.0) .12
Thickness of coverage (μm)† 86.4 (60.2-121.4) 62.2 (44.5-87.7) 24 (−15 to 62) .17
Apposition ISA struts 0.1 (0.0 to −)‡ 0.4 (0.1-1.4) −0.3 (−1.3 to 0.1) .15
Lesions with
≥10% ISA struts 0.0 (0.0-0.7) 0.0 (0.0-0.7) −0.0 (−0.7 to 0.6) .49
≥5% ISA struts 0.0 (0.0-1.1) 2.7 (0.0-25.0) −2.6 (−24.9 to −0.0) .042
Any ISA struts 18.6 (2.3-60.3) 71.3 (27.0-95.1) −48.7 (−85.1 to 5.2) .08
Weighted percentages and differences are derived from medians and 25th and 97th percentiles of the corresponding posterior distributions in WinBugs. CrI indicates credibility
interval.
⁎ Prespecified primary outcome of OCT substudy.
†Averages are geometric means and differences in geometric means derived from posterior distributions in WinBugs (Imperial College and Medical Research Council, London, UK).
‡Note that the upper limit of the 95% CrI could not be estimated.
Comparison
Figure 4
Trend graph showing the weighted percentage of covered struts at
9 and 24 months for both types of stent.
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coverage achieved.
To our knowledge, this is the first sequential OCT
study suggesting that different types of stent can
promote different healing rates. This may be relevant
for tailoring the duration of dual-antiplatelet therapy
after stenting.Limitations
The refusal of some patients to undergo the 24-month
OCT follow-up is the main limitation of this study. It
might have induced some selection bias because the
patients with more favorable outcome might have been
more prone to refuse a second invasive follow-up. The
lack of statistical significance at 9 months in this second
analysis is also explained by the substantial loss of
statistical precision resulting from the restricted sample
size and not contradictory with the previously pub-
lished results.9 The high percentage of refusals turned
this study underpowered to detect the difference of the
same magnitude.
Figure 5
Spread-out-vessel charts showing the spatial distribution of uncovered struts at 9 and 24 months in the matched stents.
Gutiérrez-Chico et al 929
American Heart Journal
Volume 162, Number 5Conclusion
Better strut coverage of a BES with a biodegradable
polymer and abluminal coating as compared with a first-
generation SES with a durable polymer at 9 months was
followed by improvement in coverage of the latter stent
and similar long-term OCT outcomes in both stent types
at 24 months.Disclosures
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